You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
News and reporting on colorectal cancer.
The assay is Guardant Health’s first commercially available product for clinical management of early-stage tumors and is initially focused on colorectal cancer.
The firm said that due to a negative coverage decision and capital constraints, it is evaluating options including a sale by a public takeover or an asset deal.
CellMax also completed a Series C financing round to speed up development of itsFirstSight liquid biopsy test to detect colorectal cancer and precancer polyps.
The company is collaborating with the University of Leeds under a new grant, aiming to collect prospective validation and economic data that could support clinical adoption.
The firm said its test can be used to evaluate blood samples from people who present with suspicious growths in the breast, lung, prostate, colon, or brain.
During a conference call, company executives also discussed results from the SMART NIPT trial and their outlook for Natera's three businesses.
The company doesn’t expect significant revenue from the test this year, but executives said that they are already seeing positive reception trends.
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
The company focuses on tests for early cancer screening tests and offers two fecal immunochemical tests approved in China.
The company is getting ready to offer cancer patients every type of molecular cancer diagnostics, including testing for minimal residual disease.